Nexalis Therapeutics Limited (NX1)
ASX ASX Primary Summary
Nexalis Therapeutics Limited (NX1) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nexalis Therapeutics Limited ever had a stock split?
Nexalis Therapeutics Limited Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | - CEO | ASX Exchange | AU0000456733 ISIN |
| Australia Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
InhaleRx Limited is a pioneer in the pharmaceutical industry, focusing on the development and commercialization of advanced medical drug delivery systems in Australia. The company has a specialized interest in creating inhaled drug formulations, catering to a broad spectrum of medical needs. Initially known as Lifespot Health Ltd, the enterprise underwent a significant rebranding, shifting its name to InhaleRx Limited in October 2021, marking a new chapter in its endeavor to innovate within the healthcare sector. Founded in 2016 and having its foundations in Melbourne, Australia, InhaleRx Limited continues to make strides in offering novel solutions for inhalation drug delivery.
Products and Services
Medihale Inhaler: The centerpiece of InhaleRx’s product line is the Medihale inhaler, a state-of-the-art sealed pod inhaler designed for use with a variety of inhaled formulations. This device epitomizes the company’s dedication to improving patient experience and treatment efficacy through innovative technology. The Medihale inhaler is equipped with features that ensure precise dosage, ease of use, and improved drug administration efficiency, making it a valuable tool in the management of respiratory conditions.
